Ignite Creation Date:
2025-12-25 @ 2:34 AM
Ignite Modification Date:
2026-03-11 @ 9:05 PM
Study NCT ID:
NCT05048134
Status:
TERMINATED
Last Update Posted:
2024-09-19
First Post:
2021-08-31
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
HRS2300-I-101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None